Zolpidem

Pronunciation: ZOL-pi-dem.

Generic name
zolpidem tartrate
Drug class
Non-benzodiazepine sedative-hypnotic ('Z-drug'), imidazopyridine, GABA-A receptor positive modulator
Form
Tablet (immediate-release and, in some markets, extended-release or sublingual)
Route
Oral (also available as a sublingual tablet in some markets)
Legal status
Prescription-only, controlled substance

Availability and supply rules vary by country

Trade names by country: United States · United Kingdom · Canada · Australia

Australia: Stilnox (zolpidem tartrate) (5) · Full directory

What zolpidem tartrate is and how it works

Zolpidem is a prescription-only sedative-hypnotic ('sleeping pill') used for the short-term treatment of insomnia, particularly trouble falling asleep. It carries a serious boxed warning about complex sleep behaviors -- see above. (1) (2) (4)

Take zolpidem exactly as your prescriber directs, only when you can devote a full night (at least 7-8 hours) to sleep, and only for the short period recommended. Never combine it with alcohol. If you have been taking it regularly, never stop it abruptly on your own -- ask your prescriber how to reduce the dose safely. The one exception is if you experience a complex sleep behavior (see boxed warning): contact your prescriber immediately and avoid taking any further doses in that specific situation.

Mechanism of action: how zolpidem tartrate works

Zolpidem is an imidazopyridine that acts as a positive allosteric modulator at the GABA-A receptor, selective for the omega-1 (alpha-1-containing) receptor subtype, increasing chloride channel opening and neuronal inhibition to promote sleep onset, with less effect on sleep architecture than older benzodiazepines at recommended doses. (1) (2)

What zolpidem tartrate is used for

Short-term treatment of insomnia

Used for a short period to help with difficulty falling asleep (and, per some markets' labelling, frequent nighttime or early-morning waking) when insomnia is significantly affecting daily functioning. (1) (2) (4)

Before taking zolpidem tartrate

Do not take / not appropriate for

  • Do not take zolpidem if you have previously experienced a complex sleep behavior (such as sleep-walking or sleep-driving) after taking it. (United States, Canada, Australia) (1) (4) (5)
  • Do not take zolpidem if you have myasthenia gravis, severe liver problems, obstructive sleep apnoea, or severe/acute breathing problems. (United Kingdom, Canada) (2) (4)
  • Do not drink alcohol while taking zolpidem. (all countries) (2) (5)
  • Do not take zolpidem if you are allergic to it or any of its ingredients. (all countries) (1)

Tell your clinician about

  • Any personal or family history of sleepwalking, or any previous complex sleep behaviour on a sedative-hypnotic medicine.
  • Any history of depression, mental illness, or suicidal thoughts.
  • Any history of alcohol or drug misuse or dependence.
  • Liver or breathing problems, including sleep apnoea.
  • All other medicines you take, especially anything else that makes you sleepy (opioids, other sedatives, some antidepressants).
  • If you are pregnant, planning pregnancy, or breastfeeding.
  • Your sex -- your prescriber will use this, along with other factors, when deciding your starting dose in some countries (see How to take).
(1) (2) (4) (5)

How to take zolpidem tartrate

  • Take zolpidem exactly as prescribed, as a single dose immediately before bedtime -- do not take a second dose during the same night.
  • Only take it when you can devote a full night (at least 7-8 hours) to sleep before you need to be fully alert again, such as for driving.
  • Do not take it with or right after a meal -- this can slow how quickly it works.
  • Use it for the shortest time your prescriber recommends -- typically no more than a few weeks, and often just a matter of days.
  • If you have been taking zolpidem regularly and need to stop, do not stop abruptly on your own -- your prescriber will taper the dose down gradually to reduce withdrawal risk.
  • Exception: if you experience a complex sleep behavior (see boxed warning above), contact your prescriber immediately and do not take zolpidem again until you have spoken with them -- do not wait.
(1) (2) (4)

Procedures and treatment changes

Tell the treating team before surgery, procedures, or any medicine change. Do not alter treatment without the responsible clinician. (1) (2) (3) (4) (5) (7)

Missed dose

Zolpidem is taken only when you are about to go to sleep with a full night available, not on a fixed daily schedule -- if you did not take it at bedtime and it is now close to morning or you no longer have at least 7-8 hours before you need to be alert, skip that dose rather than taking it late. Contact your prescriber if you are unsure.

Overdose

Seek emergency medical attention if you or someone else may have taken too much zolpidem, especially if combined with alcohol or other sedating medicines. Signs can include extreme drowsiness, slowed or difficult breathing, or loss of consciousness. (1) (2)

Side effects

Side effects and their urgency vary; report severe, persistent, or concerning symptoms.

Drowsiness the next day.

What to notice: Drowsiness the next day.

What to do: Discuss persistent or troublesome symptoms with the treating clinician or pharmacist. (1) (2)

Dizziness.

What to notice: Dizziness.

What to do: Discuss persistent or troublesome symptoms with the treating clinician or pharmacist. (1) (2) (5)

Headache.

What to notice: Headache.

What to do: Discuss persistent or troublesome symptoms with the treating clinician or pharmacist. (2) (5)

Diarrhoea, nausea, or other stomach upset.

What to notice: Diarrhoea, nausea, or other stomach upset.

What to do: Discuss persistent or troublesome symptoms with the treating clinician or pharmacist. (1) (2)

Memory problems (difficulty forming new memories after taking a dose).

What to notice: Memory problems (difficulty forming new memories after taking a dose).

What to do: Discuss persistent or troublesome symptoms with the treating clinician or pharmacist. (2) (5)

A 'drugged' or hungover feeling, especially with longer-term use.

What to notice: A 'drugged' or hungover feeling, especially with longer-term use.

What to do: Discuss persistent or troublesome symptoms with the treating clinician or pharmacist. (1)

Serious warnings

Complex sleep behaviors (sleep-walking, sleep-driving, and similar) — boxed_warning

Symptoms: Walking, driving, preparing and eating food, making phone calls, or other activity while not fully awake, usually with no memory of it afterward.

Action: Contact your prescriber immediately and do not take zolpidem again until you have spoken with them, if this happens to you or someone taking it -- this can occur after any dose, even the first or the lowest recommended dose, and has led to serious injury and death. (1) (4) (5)

Next-day impairment affecting driving or other alert tasks — high caution

Symptoms: Feeling less alert than usual, slowed reaction times, or drowsiness the morning after a dose -- you can be impaired even if you feel fully awake.

Action: Do not drive or do anything requiring full alertness the morning after taking zolpidem, especially if you did not have a full 7-8 hours of sleep, took a higher dose, or are female (higher morning blood levels are more likely). Discuss your specific risk with your prescriber. (1) (2) (7)

Severe sedation, slowed breathing, or overdose signs (especially combined with opioids, alcohol, or other sedatives) — emergency

Symptoms: Extreme drowsiness, slow or difficult breathing, unresponsiveness.

Action: Seek emergency medical help immediately. Never combine zolpidem with alcohol, opioid pain medicines, or other sedatives unless specifically directed and monitored by your prescriber. (2) (4)

Withdrawal symptoms after stopping regular or prolonged use — high caution

Symptoms: Rebound insomnia, anxiety, tremor, sweating, agitation, confusion, and in more severe cases cramps, vomiting, convulsions, or delirium.

Action: Never stop zolpidem abruptly on your own after taking it regularly -- ask your prescriber to guide a gradual, tapered reduction. (This is separate from the boxed warning above: if you experience a complex sleep behavior, that specific situation calls for an immediate call to your prescriber, without taking any further doses in the meantime.) (1) (2) (4)

New or worsening depression, unusual thoughts, or behaviour changes — high caution

Symptoms: Worsening mood, agitation, unusual or aggressive behaviour, or thoughts of self-harm.

Action: Contact your prescriber promptly, or seek emergency help if there is any risk of self-harm. (5)

Interactions

  • Alcohol: significantly increases sedation and impairment risk -- avoid entirely while taking zolpidem. (2) (5)
  • Opioid pain medicines: combined use can cause profound sedation, breathing difficulty, coma, or death -- only combine if your prescriber decides there is no alternative, at the lowest doses and shortest duration needed, with monitoring. (2) (4)
  • Other sedating medicines (other sleep aids, some antidepressants, anti-anxiety medicines): additive drowsiness and CNS depression. (1) (2)
  • Certain antifungal medicines (e.g. ketoconazole) and other strong CYP3A4 inhibitors can raise zolpidem levels in the body, increasing side-effect risk -- a dose adjustment may be needed. (1) (2)
  • Rifampin and St John's wort can make zolpidem less effective. (1) (2)
  • Sertraline and some other antidepressants can raise zolpidem blood levels. (1)

Pregnancy, breastfeeding, kidney/liver function, age

Pregnancy

Use in pregnancy is generally not recommended. Third-trimester use has been linked to a risk of respiratory depression and sedation in the newborn; some labels also describe risks of low body temperature, floppiness (hypotonia), and withdrawal symptoms in the baby. Discuss any use during pregnancy with your prescriber. (1) (2) (3) (4) (5) (7)

Breastfeeding

Small amounts of zolpidem pass into breast milk. Some official sources advise against breastfeeding while taking it, or recommend pumping and discarding milk for a specified period (up to 23 hours) after a dose -- discuss the right approach with your prescriber. (1) (2) (3) (4) (5) (7)

Children

Not established as safe and effective in children, and not authorised for paediatric use in the sources reviewed. (1) (2) (3) (4) (5) (7)

Elderly

Older adults are generally more sensitive to zolpidem and are usually started on the lower dose (5 mg), with long-term use generally avoided and closer monitoring for falls, confusion, or excess sedation. (1) (2) (3) (4) (5) (7)

Hepatic_impairment

Liver problems slow the clearance of zolpidem -- lower starting doses are used, and severe hepatic impairment is a contraindication in several markets. (1) (2) (3) (4) (5) (7)

Renal_impairment

Not specifically addressed as needing dose adjustment in the primary sources reviewed, though general caution with any sedating medicine is reasonable. (1) (2) (3) (4) (5) (7)

Source_ids

US-DAILYMED-AMBIEN-2026,UK-EMC-ZOLPIDEM-2026,CA-HC-SUBLINOX-2022,AU-TGA-STILNOX-PI-2026 (1) (2) (3) (4) (5) (7)

Monitoring

Before starting

  • Screen for a personal/family history of sleepwalking or prior complex sleep behaviour on a sedative-hypnotic
  • Screen for sleep apnoea, significant breathing problems, myasthenia gravis, and severe liver disease
  • Review other sedating medicines and alcohol use
  • Assess for depression or suicide risk

During treatment

  • Re-evaluate if insomnia has not improved after the expected short course (often within about 1-2 weeks) -- this may signal an underlying condition needing separate treatment.
  • Watch for any new complex sleep behaviour, worsening mood, or signs of dependence.
  • Periodic review to confirm continued need, since long-term use is generally not recommended.
(1) (4) (5)

Storage

Store at room temperature, around 20-25°C (68-77°F). Keep in a secure place out of reach of others, given the risk of misuse, dependence, and diversion.

Professional information

Clinician-facing context only, sourced from the current US FDA prescribing information, UK emc SmPC, Health Canada Sublinox monograph, and Australian Stilnox PI; verify against the current full label before prescribing.

United States / Canada

Indication: Short-term insomnia

Dose summary: Women: 5 mg initial (immediate-release), max 10 mg/day. Men: 5-10 mg initial, max 10 mg/day. Elderly or hepatic impairment: 5 mg regardless of sex. Single nightly dose, immediately before bedtime, with at least 7-8 hours of sleep opportunity remaining; not with or immediately after food. Canada: usual course 7-10 days; use beyond 2-3 weeks requires full re-evaluation; taper to discontinue.

Renal context: Not established as needing specific adjustment in the sources reviewed. (1) (4)

United Kingdom

Indication: Short-term insomnia

Dose summary: 10 mg at bedtime (5 mg in elderly/debilitated patients or starting dose in hepatic impairment, may increase to 10 mg in non-elderly adults if needed). Duration should not exceed 4 weeks including tapering; single intake only.

Renal context: Not specified in the source reviewed. (2)

Mechanism of action

Hepatic guidance

Clearance is reduced in hepatic impairment; lower doses and caution are required, with severe hepatic impairment contraindicated in several markets.

Overdose note

Supportive care is the mainstay; flumazenil may reverse sedation but carries a seizure risk, particularly in patients with a seizure history or mixed-drug overdose; zolpidem is not effectively removed by dialysis. (1) (2)

Frequently asked questions

What is the boxed warning for zolpidem about?

Zolpidem carries a serious warning about complex sleep behaviors -- doing things like walking, driving, or preparing food while not fully awake, usually with no memory of it afterward. This has caused serious injuries and deaths, and can happen after any dose, even the first one or the lowest recommended dose. If this happens to you, contact your prescriber immediately and do not take zolpidem again until you have spoken with them. (1) (4) (5)

Why do some countries recommend a lower dose for women?

In the United States and Canada, regulators require a lower starting dose for women (5 mg instead of 5-10 mg for men) because zolpidem clears from a woman's body more slowly, which can leave more of the drug in the system the next morning and increase the risk of impaired driving or alertness. This specific sex-based dosing rule is not part of every country's label -- for example, the UK label reviewed for this page does not include it. (7) (4) (2)

Can I just stop taking zolpidem if I've been using it for a while?

If you have been taking it regularly, do not stop abruptly on your own -- this can cause withdrawal symptoms such as rebound insomnia, anxiety, or in more severe cases seizures. Ask your prescriber to guide a gradual dose reduction. The one exception is if you experience a complex sleep behavior: in that specific case, contact your prescriber right away and do not take another dose until you have spoken with them. (1) (4)

Is zolpidem available in the US, UK, Europe, Canada, Australia, and New Zealand?

It is confirmed authorised in the United States, United Kingdom, European Union (e.g. Germany, Spain, Romania), Canada, and Australia. New Zealand is uncertain: zolpidem was classified as a controlled drug there in 2023, but we could not confirm a currently marketed product or an up-to-date Medsafe data sheet, and it is described as rarely prescribed in New Zealand. (1) (2) (3) (4) (5) (6)

What is the mechanism of action of zolpidem tartrate?

Zolpidem is an imidazopyridine that acts as a positive allosteric modulator at the GABA-A receptor, selective for the omega-1 (alpha-1-containing) receptor subtype, increasing chloride channel opening and neuronal inhibition to promote sleep onset, with less effect on sleep architecture than older benzodiazepines at recommended doses. (1) (2)

What is the generic name of Zolpidem?

The generic name is zolpidem tartrate. (1)

What class of drug is zolpidem tartrate?

Zolpidem is classed as: Non-benzodiazepine sedative-hypnotic ('Z-drug'), imidazopyridine, GABA-A receptor positive modulator. (1)

References

  1. AMBIEN (zolpidem tartrate) tablets -- full prescribing informationU.S. Food and Drug Administration / DailyMed (NIH), full prescribing information, initial US approval 1992 · United States · accessed 2026-07-29 · source 1
  2. Zolpidem Tartrate 10mg Tablets -- Summary of Product Characteristicselectronic medicines compendium (emc), United Kingdom -- Zentiva Pharma UK Limited · United Kingdom · accessed 2026-07-29 · source 2
  3. List of nationally authorised medicinal products -- Active substance: zolpidem, Procedure No. PSUSA-00003151-202308European Medicines Agency (EMA), Human Medicines Division · European Union · accessed 2026-07-29 · source 3
  4. SUBLINOX (zolpidem tartrate sublingual orally disintegrating tablets, 5 mg and 10 mg) -- Product Monograph including Patient Medication InformationHealth Canada product monograph, Bausch Health, Canada Inc. · Canada · accessed 2026-07-29 · source 4
  5. STILNOX (zolpidem tartrate) Tablets -- Australian Product InformationTherapeutic Goods Administration (TGA) / sponsor (Sanofi-Aventis Australia Pty Ltd) -- Australian Product Information · Australia · accessed 2026-07-29 · source 5
  6. Search for a current Medsafe data sheet or Pharmac listing for zolpidem/Stilnox, and NZ controlled-drug scheduling statusMedsafe data sheet index search, Pharmac Schedule search, and NZ Misuse of Drugs scheduling documentation · New Zealand · accessed 2026-07-29 · source 6
  7. Questions and Answers: Risk of next-morning impairment after use of insomnia drugs; FDA requires lower recommended doses for certain drugs containing zolpidemU.S. Food and Drug Administration -- Drug Safety and Availability communication · United States · accessed 2026-07-29 · source 7

Brand names by country

Single-ingredient zolpidem tartrate names are shown separately by country. Product availability, strengths, and supply rules can change; combination products are not included here.

Priority countries

United States

  • Ambien10 mg, 12.5 mg, 6.25 mg, 5 mg · sanofi-aventis u.s. llc
  • Edluar5 mg, 10 mg · viatris specialty llc
  • Zolpidem tartrate sublingual1.75 mg, 3.5 mg · par health usa, llc

United Kingdom

  • Zolpidem Tartrate Tablets (2)MHRA licensed emc smpc confirmed PL 17780 0018 · 5 mg, 10 mg · Zentiva Pharma UK Limited

Canada

  • SUBLINOX
  • APO-ZOLPIDEM ODT
  • PMS-ZOLPIDEM ODT

Australia

  • Stilnox (zolpidem tartrate) (5)TGA ARTG 69681 registered 1999-09-10 confirmed boxed warning current PI 2026 · 10 mg · Sanofi-Aventis Australia Pty Ltd
View brands in additional countries.

European Union

Bikalm 10 mg Filmtabletten (Germany) (3), Dalparan 10 mg comprimidos (Spain) (3), Edluar 10 mg comprimate sublinguale (Romania) (3)

This page provides general reference information about zolpidem and is not a substitute for advice from the prescriber managing your treatment. All dosing and treatment decisions, especially any change to or stopping of this medicine, should be made with your prescriber -- except that experiencing a complex sleep behavior calls for an immediate call to your prescriber and avoiding further doses until you have spoken with them, as described above.

Related medicines

Related conditions